Literature DB >> 25797969

Tuberculosis and rifampicin resistance among migrants in kyrgyzstan: detection by a new diagnostic test.

Aigul Barmankulova1, Michiyo Higuchi2, Mohammad Abul Bashar Sarker2, Md Abdul Alim3, Nobuyuki Hamajima2.   

Abstract

This cross-sectional study aimed to describe suspected tuberculosis (TB) cases among migrants in Kyrgyzstan and to estimate the accuracy of Xpert MTB/RIF, which has been operated in Kyrgyzstan since 2012. Characteristics of 3,714 suspected cases among migrants were analysed. In addition, by using data of 300 cases with culture results, sensitivity and specificity of Xpert MTB/RIF, both for detection of TB and rifampicin susceptibility, were assessed. Among 3,714 suspected cases, 56.1% were male, and the median age was 35 years old. Of the suspected cases, 17.2% were previously-treated. In total, 809 (21.8%) were smear-positive; 36.8% among previously-treated cases and 18.7% among new cases. Among 300 selected participants, 235 (78.3%) were culture-positive. Of those who were confirmed as TB positive, recurrent cases showed a higher proportion of rifampicin resistance than new cases (59.3% vs 42.6%). For detection of TB, the sensitivity and specificity of XpertMTB/RIF (81.3% and 98.2%) were higher than those of microscopy (70.2% and 71.4%). Sensitivity and specificity for detection of rifampicin resistance were 96.8% and 91.8%, respectively. The rifampicin resistance rate in the study population was higher than the national average. Xpert MTB/RIF showed higher accuracy in detecting TB cases than microscopic diagnosis. Higher accuracy and earlier detection of drug susceptibility is especially important for those who have difficulty in accessing healthcare and those who are easily lost from tracking, including migrants.

Entities:  

Keywords:  Kyrgyzstan; MDR-TB; Migrants; Tuberculosis; Xpert MTB/RIF

Year:  2015        PMID: 25797969      PMCID: PMC4361506     

Source DB:  PubMed          Journal:  Nagoya J Med Sci        ISSN: 0027-7622            Impact factor:   1.131


  8 in total

1.  MDR tuberculosis--critical steps for prevention and control.

Authors:  Eva Nathanson; Paul Nunn; Mukund Uplekar; Katherine Floyd; Ernesto Jaramillo; Knut Lönnroth; Diana Weil; Mario Raviglione
Journal:  N Engl J Med       Date:  2010-09-09       Impact factor: 91.245

Review 2.  Xpert® MTB/RIF assay: development, evaluation and implementation of a new rapid molecular diagnostic for tuberculosis and rifampicin resistance.

Authors:  Stephen D Lawn; Mark P Nicol
Journal:  Future Microbiol       Date:  2011-09       Impact factor: 3.165

Review 3.  Rapid molecular TB diagnosis: evidence, policy making and global implementation of Xpert MTB/RIF.

Authors:  Karin Weyer; Fuad Mirzayev; Giovanni Battista Migliori; Wayne Van Gemert; Lia D'Ambrosio; Matteo Zignol; Katherine Floyd; Rosella Centis; Daniela M Cirillo; Enrico Tortoli; Chris Gilpin; Jean de Dieu Iragena; Dennis Falzon; Mario Raviglione
Journal:  Eur Respir J       Date:  2012-11-22       Impact factor: 16.671

Review 4.  Advances in tuberculosis diagnostics: the Xpert MTB/RIF assay and future prospects for a point-of-care test.

Authors:  Stephen D Lawn; Peter Mwaba; Matthew Bates; Amy Piatek; Heather Alexander; Ben J Marais; Luis E Cuevas; Timothy D McHugh; Lynn Zijenah; Nathan Kapata; Ibrahim Abubakar; Ruth McNerney; Michael Hoelscher; Ziad A Memish; Giovanni Battista Migliori; Peter Kim; Markus Maeurer; Marco Schito; Alimuddin Zumla
Journal:  Lancet Infect Dis       Date:  2013-03-24       Impact factor: 25.071

Review 5.  Xpert® MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults.

Authors:  Karen R Steingart; Hojoon Sohn; Ian Schiller; Lorie A Kloda; Catharina C Boehme; Madhukar Pai; Nandini Dendukuri
Journal:  Cochrane Database Syst Rev       Date:  2013-01-31

6.  Barriers in accessing to tuberculosis care among non-residents in Shanghai: a descriptive study of delays in diagnosis.

Authors:  Weibing Wang; Qingwu Jiang; Abu Saleh M Abdullah; Biao Xu
Journal:  Eur J Public Health       Date:  2007-04-04       Impact factor: 3.367

7.  Feasibility, diagnostic accuracy, and effectiveness of decentralised use of the Xpert MTB/RIF test for diagnosis of tuberculosis and multidrug resistance: a multicentre implementation study.

Authors:  Catharina C Boehme; Mark P Nicol; Pamela Nabeta; Joy S Michael; Eduardo Gotuzzo; Rasim Tahirli; Ma Tarcela Gler; Robert Blakemore; William Worodria; Christen Gray; Laurence Huang; Tatiana Caceres; Rafail Mehdiyev; Lawrence Raymond; Andrew Whitelaw; Kalaiselvan Sagadevan; Heather Alexander; Heidi Albert; Frank Cobelens; Helen Cox; David Alland; Mark D Perkins
Journal:  Lancet       Date:  2011-04-18       Impact factor: 79.321

8.  Barriers to accessing TB diagnosis for rural-to-urban migrants with chronic cough in Chongqing, China: a mixed methods study.

Authors:  Qian Long; Ying Li; Yang Wang; Yong Yue; Cheng Tang; Shenglan Tang; S Bertel Squire; Rachel Tolhurst
Journal:  BMC Health Serv Res       Date:  2008-10-02       Impact factor: 2.655

  8 in total
  3 in total

1.  Xpert MTB/RIF and Xpert MTB/RIF Ultra for pulmonary tuberculosis and rifampicin resistance in adults.

Authors:  David J Horne; Mikashmi Kohli; Jerry S Zifodya; Ian Schiller; Nandini Dendukuri; Deanna Tollefson; Samuel G Schumacher; Eleanor A Ochodo; Madhukar Pai; Karen R Steingart
Journal:  Cochrane Database Syst Rev       Date:  2019-06-07

2.  Tuberculosis among migrants in Bishkek, the capital of the Kyrgyz Republic.

Authors:  O Goncharova; O Denisiuk; R Zachariah; K Davtyan; D Nabirova; C Acosta; A Kadyrov
Journal:  Public Health Action       Date:  2017-09-21

Review 3.  Xpert MTB/RIF assay for the diagnosis of rifampicin resistance in different regions: a meta-analysis.

Authors:  Kaican Zong; Chen Luo; Hui Zhou; Yangzhi Jiang; Shiying Li
Journal:  BMC Microbiol       Date:  2019-08-05       Impact factor: 3.605

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.